Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Clinical trial NCT03703297 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03703297
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-27
- Primary completion
- 2024-01-15
- Enrollment
- 730
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.